152 results
Page 4 of 8
8-K
EX-99.1
ugk409 kjndj1
29 Mar 19
Millendo Reports Full Year 2018 Operating and Financial Results
7:20am
8-K
6a82 j7u2b5j31ne
26 Nov 18
Other Events
9:01am
425
77y9tk4r
26 Nov 18
Business combination disclosure
8:59am
DEFM14A
nn92azgp
6 Nov 18
Proxy related to merger
12:00am
424B3
gi4rayt620y6mhy
5 Nov 18
Prospectus supplement
3:51pm
S-4/A
rodda5g
1 Nov 18
Registration of securities issued in business combination transactions (amended)
5:32pm
S-4/A
EX-10.1
onz05l zrgs
1 Nov 18
Registration of securities issued in business combination transactions (amended)
5:32pm
8-K
EX-99.1
d2jst94yrt1w7r
1 Nov 18
OvaScience and Millendo Therapeutics Provide Update on Merger Agreement and Financing
5:01pm
425
EX-99.1
ls5a2ybu
1 Nov 18
Business combination disclosure
5:00pm
8-K
EX-99.4
apey6xyf
9 Aug 18
OvaScience and Millendo Therapeutics Announce Merger to Create Leading Rare Endocrine Disease Company
5:19pm
8-K
EX-2.1
864c hlg4m5c43s8a8rp
9 Aug 18
OvaScience and Millendo Therapeutics Announce Merger to Create Leading Rare Endocrine Disease Company
5:19pm
8-K
EX-99.1
ndu2ct4gu59 8i3
9 Aug 18
OvaScience and Millendo Therapeutics Announce Merger to Create Leading Rare Endocrine Disease Company
5:19pm
425
EX-2.1
glm4h5cezw174
9 Aug 18
Business combination disclosure
5:17pm
425
EX-99.4
lnmp9iw mq41lk3wd610
9 Aug 18
Business combination disclosure
5:17pm